SCHEMBL28088014

SCHEMBL28088014

NNC(=O)c1nc(C(=O)Cc2ccccc2)c(C(F)(F)F)nc1N

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.42
P2RX7 Q99572 1/20 0.39
ALDH1A1 P00352 5/20 0.38
KDM4E B2RXH2 4/20 0.38
SCNN1A P37088 4/20 0.38
HPGD P15428 3/20 0.38
GLA P06280 2/20 0.38
HSD17B10 Q99714 2/20 0.38
GAA P10253 2/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
NFKB1 P19838 1/20 0.38
THPO P40225 1/20 0.38
HIF1A Q16665 1/20 0.38
FTO Q9C0B1 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
GMNN O75496 1/20 0.37
BLM P54132 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27976388 0.80 CFTR (0.44) CES1
SCHEMBL14784661 0.77 P2RX7 (0.40) P2RX7ALDH1A1KDM4EGAAMAPT
SCHEMBL28088010 0.75 CES1 (0.38) CES1ALDH1A1GLAHSD17B10GAA
SCHEMBL14784182 0.75 KMT2A (0.45) CES1ALDH1A1KDM4EGLAGAA
SCHEMBL14784270 0.72 CFTR (0.42) P2RX7ALDH1A1KDM4EGAANPC1
SCHEMBL13201034 0.65 ATR (0.53) CES1MAPTATR
SCHEMBL5080 0.65 MEN1 (0.65) CES1ALDH1A1HPGDGAACYP1A2
Hydrochloric Acid SCHEMBL28363647 0.63 MEN1 (0.63) CES1ALDH1A1HPGDGAACYP1A2
SCHEMBL27976390 0.63 P2RX7 (0.46) P2RX7ATR
SCHEMBL27688627 0.63 P2RX7 (0.46) P2RX7ALDH1A1KDM4EGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103946221-B heterocyclic compounds for the treatment of cystic fibrosis 诺华股份有限公司 2016-08-03 CN disclosed
CN-103946221-A Heterocyclic compounds for the treatment of cystic fibrosis NOVARTIS AG 2014-07-23 CN disclosed